


# Brand Access Marketplace Dynamics

## Autoimmune Market

**Brand Access Marketplace Dynamics** assesses the current and future access environment for your therapeutic market.

**Brand Access Marketplace Dynamics** answers your questions so you can identify opportunities and risks for your brand.

- How do market access stakeholders influence access in your therapeutic market?
- How will market access stakeholder management and contracting for the brands in this therapeutic market evolve over the next two years?
- How are market access stakeholders responding to key market events in this therapeutic market?



### You can use **Brand Access Marketplace Dynamics** to:

- Keep** your finger on the pulse of market evolution
- Understand** the shift in influence on access between payers and organized providers
- Understand** current and future payer management of this therapeutic market
- Identify** opportunities and risks for your brand's access

<p><b>February 2017</b> Autoimmune Market Access Stakeholder Drug Management Landscape</p>	<ul style="list-style-type: none"> <li>▪ Key organized stakeholders that impact access to products in your therapeutic market</li> <li>▪ Stakeholder tactics that impact access to your products</li> <li>▪ Stakeholder's capabilities in managing physician and patient access</li> <li>▪ Brand-specific management tactics that impact access by key stakeholders</li> </ul>
<p><b>April 2017</b> <b>July 2017</b> <b>October 2016/7</b> Autoimmune Market Access Stakeholder Drug Management Pulse</p>	<ul style="list-style-type: none"> <li>▪ Customer reaction to market events that will shape management in your therapeutic market</li> <li>▪ Pulses will cover customer reaction to up to five market events each quarter</li> <li>▪ Anticipated market events in 2017 include:             <ul style="list-style-type: none"> <li>– Market entry of biosimilar products</li> <li>– Expanded guidelines or treatment recommendations for inflammatory autoimmune conditions</li> <li>– FDA approvals and market launch of new products, including potentially:                 <ul style="list-style-type: none"> <li>– Baricitinib, sarilumab, ABT-494, and sirukumab for RA</li> <li>– Brodalumab for psoriasis</li> <li>– Taltz, Orencia, Simponi Aria, Xeljanz for psoriatic arthritis</li> <li>– Stelara, Xeljanz, ozanimod, etrolizumab for Crohn's disease and/or ulcerative colitis</li> </ul> </li> <li>– Release of high profile head-to-head clinical trial data</li> </ul> </li> </ul>
<p><b>May 2017</b> Autoimmune Market Access Stakeholder Drug Management Outlook 2019</p>	<ul style="list-style-type: none"> <li>▪ Evolving stakeholder capabilities over next two years             <ul style="list-style-type: none"> <li>– Eg, SP mandates, benefit design, reimbursement models, site-of-care management, preferred agent selection, clinical pathways</li> </ul> </li> <li>▪ Brand-level scenarios of predicted stakeholder management</li> <li>▪ Evolving pricing and contracting environment</li> <li>▪ Assessment of future/near term access risks by brand</li> </ul>

**Clients receive:**

 <p><b>On-call access to our subject matter experts for your inquiries</b></p>	 <p><b>Access to our website, customized for your organization</b></p>
 <p><b>Client-exclusive webinar</b></p>	 <p><b>Unlocked PowerPoint slides</b></p>
 <p><b>On-site and virtual presentations with research leaders</b></p>	 <p><b>Access to source data</b></p>
 <p><b>Opportunity for input into research topics covered within the service</b></p>	 <p><b>Specific recommendations for your organization</b></p>

Health Strategies Group reserves the right to change the timing and/or topics of its syndicated research publications.